AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34487415 — intervention group
Group type: COMPARATOR
Intervention: No stent overlap
Number of subjects: 5605
Study 33407204 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation-based balance training (PBT) - three 30-minute sessions in the Computer Assisted Rehabilitation Environment.
Number of subjects: 80
Study 33407204 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus PBT (intervention group).
Number of subjects: 80
Study 33407204 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 80
Study 33407204 — intervention group
Group type: EXPERIMENTAL
Intervention: PBT protocol acceptability (intervention group).
Number of subjects: 80
Study 35602629 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar plasma needle electrode
Number of subjects: 100
Study 35602629 — intervention group
Group type: COMPARATOR
Intervention: Bipolar plasma ring (control)
Number of subjects: 100
Study 34512959 — intervention group
Group type: EXPERIMENTAL
Intervention: Niclosamide (NCS) as add-on therapy to standard of care
Number of subjects: 150
Study 34512959 — intervention group
Group type: COMPARATOR
Intervention: Standard of care therapy only (Control)
Number of subjects: 150
Study 35939620 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy (iCBT)
Number of subjects: 302
Study 35939620 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 302
Study 33651849 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLLER‐MASSAGER
Number of subjects: 14
Study 33651849 — intervention group
Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 14
Study 32370804 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal counseling sessions (4 sessions)
Number of subjects: 108
Study 32370804 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 108
Study 35044927 — intervention group
Group type: EXPERIMENTAL
Intervention: My Possible Self (MPS)
Number of subjects: 169
Study 35044927 — intervention group
Group type: EXPERIMENTAL
Intervention: NHSWBP (NHSH Staff Wellbeing Project)
Number of subjects: 169
Study 35044927 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 169
Study 33421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide gas (N2O) administration during childbirth
Number of subjects: 2070
Study 33421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine administration during childbirth
Number of subjects: 2070
Study 33421836 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both drugs with severe pain during labor
Number of subjects: 2070
Study 35332571 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 192
Study 35332571 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 192
Study 34051406 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-h light and 15-h dark regime (long dark phase, LDP)
Number of subjects: 72
Study 34051406 — intervention group
Group type: COMPARATOR
Intervention: 16-h light and 8-h dark (control)
Number of subjects: 72
Study 36222186 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GBP2 expression
Number of subjects: 286
Study 36222186 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrating GBP2 expression with TNM stage
Number of subjects: 286
Study 36222186 — intervention group
Group type: EXPERIMENTAL
Intervention: GBP2 expression
Number of subjects: 286
Study 36222186 — intervention group
Group type: EXPERIMENTAL
Intervention: GBP2
Number of subjects: 286
Study 33010242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine (Ad26.Mos4.HIV)
Number of subjects: 201
Study 33010242 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetravalent vaccine
Number of subjects: 201
Study 33010242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 35487130 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 0
Study 35487130 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints (OS)
Number of subjects: 0
Study 35487130 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 0
Study 32729269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-Switching Monopolar Radiofrequency Ablation (DSM-RFA)
Number of subjects: 80
Study 32729269 — intervention group
Group type: COMPARATOR
Intervention: Single-Switching Monopolar Radiofrequency Ablation (SSM-RFA)
Number of subjects: 80
Study 32154945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low strain rate (n = 21)
Number of subjects: 102
Study 32154945 — intervention group
Group type: EXPERIMENTAL
Intervention: High strain rate (n = 20)
Number of subjects: 102
Study 32154945 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 16)
Number of subjects: 102
Study 35876246 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal diet and exercise intervention
Number of subjects: 326
Study 35876246 — intervention group
Group type: COMPARATOR
Intervention: Sleep duration <6 hours
Number of subjects: 326
Study 33248457 — intervention group
Group type: EXPERIMENTAL
Intervention: PREVSAM model (intervention group)
Number of subjects: 0
Study 33248457 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 0
Study 35950573 — intervention group
Group type: EXPERIMENTAL
Intervention: Government performing well
Number of subjects: 357
Study 35950573 — intervention group
Group type: EXPERIMENTAL
Intervention: Government performing badly
Number of subjects: 357
Study 35950573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 357
Study 32038101 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% atropine
Number of subjects: 660
Study 32038101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 35665918 — intervention group
Group type: EXPERIMENTAL
Intervention: NRTIs included in the treatment regimen
Number of subjects: 0
Study 35665918 — intervention group
Group type: COMPARATOR
Intervention: NRTIs omitted from the treatment regimen
Number of subjects: 0
Study 34225360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein overfeeding (3% protein)
Number of subjects: 77
Study 34225360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein overfeeding (30% protein)
Number of subjects: 77
Study 34225360 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein overfeeding (20% protein)
Number of subjects: 77
Study 36418659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music intervention applied immediately after surgery
Number of subjects: 50
Study 36418659 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart music intervention
Number of subjects: 50
Study 36418659 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 50
Study 33931178 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with a central action mechanism
Number of subjects: 88
Study 33931178 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs with a peripheral action mechanism
Number of subjects: 88
Study 33931178 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine antagonists (specific drug type not mentioned)
Number of subjects: 88
Study 32320010 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialty team-based services for first-episode psychosis
Number of subjects: 0
Study 32320010 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 0
Study 33175074 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDCAP follow-up program
Number of subjects: 20
Study 33175074 — intervention group
Group type: COMPARATOR
Intervention: Routine care without NIDCAP
Number of subjects: 20
Study 35219340 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program
Number of subjects: 40
Study 35219340 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 34745397 — intervention group
Group type: EXPERIMENTAL
Intervention: Kiatsu with Ki training
Number of subjects: 69
Study 35854251 — intervention group
Group type: EXPERIMENTAL
Intervention: ImRs (Imagery Rescripting)
Number of subjects: 205
Study 35854251 — intervention group
Group type: EXPERIMENTAL
Intervention: PE (Prolonged Exposure)
Number of subjects: 205
Study 35854251 — intervention group
Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 205
Study 35854251 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous PTSD treatment
Number of subjects: 205
Study 35854251 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential PTSD treatment
Number of subjects: 205
Study 32713006 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal-specific ONS
Number of subjects: 0
Study 32713006 — intervention group
Group type: COMPARATOR
Intervention: Macronutrient-matched ONS
Number of subjects: 0
Study 32713006 — intervention group
Group type: COMPARATOR
Intervention: Standard ONS
Number of subjects: 0
Study 36127722 — intervention group
Group type: COMPARATOR
Intervention: Sublay Mesh‐Only Repair
Number of subjects: 56
Study 36127722 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Component Separation with Transversus Abdominis Release (TAR)
Number of subjects: 56
Study 33609066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypokalaemia (serum potassium <4 mmol/L)
Number of subjects: 4822
Study 33609066 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperkalaemia (serum potassium >5 mmol/L)
Number of subjects: 4822
Study 33609066 — intervention group
Group type: COMPARATOR
Intervention: Normokalaemia (serum potassium 4–5 mmol/L)
Number of subjects: 4822
Study 33609066 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause and cardiovascular death
Number of subjects: 4822
Study 32119749 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib (ODN)
Number of subjects: 386
Study 34695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI
Number of subjects: 735
Study 34695841 — intervention group
Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI
Number of subjects: 735
Study 34695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI (subgroup analysis for mediocentrally located tumors)
Number of subjects: 735
Study 34695841 — intervention group
Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI (subgroup analysis for mediocentrally located tumors)
Number of subjects: 735
Study 34695841 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional nodal irradiation with IMNI (subgroup analysis for breast cancer mortality)
Number of subjects: 735
Study 34695841 — intervention group
Group type: COMPARATOR
Intervention: Regional nodal irradiation without IMNI (subgroup analysis for breast cancer mortality)
Number of subjects: 735
Study 34726661 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (ET) for 12 weeks
Number of subjects: 31
Study 34726661 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC) for 12 weeks
Number of subjects: 31
Study 32450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) alone
Number of subjects: 150
Study 32450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) with liraglutide 3.0 mg/d
Number of subjects: 150
Study 32450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Behavioral Therapy (IBT) with liraglutide and a 12-week meal replacement diet (Multi-component)
Number of subjects: 150
Study 32450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Early weight loss
Number of subjects: 150
Study 32450367 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring and medication adherence
Number of subjects: 150
Study 35947347 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin pamoate PR 3-month (15 mg per injection, once every 12 weeks)
Number of subjects: 300
Study 35947347 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin acetate PR 1-month (3.75 mg per injection, once every 4 weeks)
Number of subjects: 300
Study 35947347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 300
Study 34865631 — intervention group
Group type: EXPERIMENTAL
Intervention: Research MRI (3 Tesla Philips Ingenia®) at baseline and 6 months
Number of subjects: 86
Study 34865631 — intervention group
Group type: EXPERIMENTAL
Intervention: Research MRI (3 Tesla Philips Ingenia®)
Number of subjects: 86
Study 34647442 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC transplant
Number of subjects: 932
Study 34647442 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC transplant from sibling donor
Number of subjects: 932
Study 34647442 — intervention group
Group type: EXPERIMENTAL
Intervention: RIC transplant from matched unrelated donor
Number of subjects: 932
Study 33298201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein 20 mg/d along with a low-calorie diet (LCD) for 10 weeks
Number of subjects: 48
Study 33298201 — intervention group
Group type: COMPARATOR
Intervention: Placebo along with a low-calorie diet (LCD) for 10 weeks
Number of subjects: 48
Study 37749609 — intervention group
Group type: EXPERIMENTAL
Intervention: Planetary Health Plate (PHP) graphic
Number of subjects: 1178
Study 37749609 — intervention group
Group type: COMPARATOR
Intervention: Control (no signage)
Number of subjects: 1178
Study 32701542 — intervention group
Group type: EXPERIMENTAL
Intervention: AnaConDa‐S (reflection group)
Number of subjects: 40
Study 32701542 — intervention group
Group type: COMPARATOR
Intervention: Circle system (low flow)
Number of subjects: 40
Study 32701542 — intervention group
Group type: COMPARATOR
Intervention: Circle system (minimal flow)
Number of subjects: 40
Study 33785016 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg/day for one week before surgery and 60 mg/day for six weeks after surgery)
Number of subjects: 0
Study 33785016 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (placebo)
Number of subjects: 0
Study 32059702 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT)
Number of subjects: 12
Study 32059702 — intervention group
Group type: COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Number of subjects: 12
Study 35925421 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifier system (TR)
Number of subjects: 12
Study 35925421 — intervention group
Group type: COMPARATOR
Intervention: Sham air purifier system (SR)
Number of subjects: 12
Study 35925421 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifier system (TR) in non-smoker rooms
Number of subjects: 12
Study 35925421 — intervention group
Group type: EXPERIMENTAL
Intervention: True air purifier system (TR) in smoker rooms
Number of subjects: 12
Study 33758231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 58
Study 33758231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32693847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM 29784 (1×10^9 cfu/kg)
Number of subjects: 1200
Study 32693847 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzymes (300 mg/kg)
Number of subjects: 1200
Study 32693847 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis DSM 29784 and Enzymes (1×10^9 cfu/kg and 300 mg/kg)
Number of subjects: 1200
Study 32693847 — intervention group
Group type: EXPERIMENTAL
Intervention: Enramycin (250 mg/kg)
Number of subjects: 1200
Study 32693847 — intervention group
Group type: COMPARATOR
Intervention: Basal diet (control)
Number of subjects: 1200
Study 33729952 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted Randomness Algorithm
Number of subjects: 0
Study 36074461 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive diabetes therapy
Number of subjects: 1441
Study 33495597 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score
Number of subjects: 2780
Study 33495597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (DBP)
Number of subjects: 2780
Study 34648753 — intervention group
Group type: EXPERIMENTAL
Intervention: Right semi-elevated side-lying position
Number of subjects: 60
Study 34436523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 34436523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 174
Study 34436523 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 174
Study 34436523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril plus Bisoprolol
Number of subjects: 174
Study 35284698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus ibuprofen (5 mg morphine with 800 mg ibuprofen)
Number of subjects: 195
Study 35284698 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus ketorolac (5 mg morphine with 30 mg ketorolac)
Number of subjects: 195
Study 35284698 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine alone (5 mg morphine)
Number of subjects: 195
Study 33190659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rPAS
Number of subjects: 32
Study 33190659 — intervention group
Group type: COMPARATOR
Intervention: Control rPAS
Number of subjects: 32
Study 33608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,000 mg)
Number of subjects: 173
Study 33608841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 32611242 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant stanol ester-enriched spread (3.0 g plant stanols/d)
Number of subjects: 90
Study 32611242 — intervention group
Group type: COMPARATOR
Intervention: Control group (spread without added plant stanol esters)
Number of subjects: 90
Study 35027281 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus the care of a pharmacist for 12 months
Number of subjects: 239
Study 35027281 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm) for 12 months
Number of subjects: 239
Study 35027281 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 intervention with a pharmacist for 6 months (for control patients who did not achieve A1C < 8%)
Number of subjects: 239
Study 35027281 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus the care of a pharmacist
Number of subjects: 239
Study 35027281 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control arm)
Number of subjects: 239
Study 35906314 — intervention group
Group type: EXPERIMENTAL
Intervention: VIPP‐PRE intervention (n=39)
Number of subjects: 73
Study 35906314 — intervention group
Group type: COMPARATOR
Intervention: Dummy intervention (n=34)
Number of subjects: 73
Study 33717089 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-marker bio-signature
Number of subjects: 1403
Study 33717089 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-marker bio-signature
Number of subjects: 1403
Study 33717089 — intervention group
Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 1403
Study 35929048 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 132
Study 35929048 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing exercises (3 times a day for 30 minutes on the first three post-operative days)
Number of subjects: 132
Study 33128847 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pantoprazole sodium enteric-coated tablets
Number of subjects: 36
Study 33128847 — intervention group
Group type: COMPARATOR
Intervention: Branded pantoprazole sodium enteric-coated tablets
Number of subjects: 36
Study 33128847 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic and branded pantoprazole sodium enteric-coated tablets
Number of subjects: 36
Study 33577235 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 40
Study 33577235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure biofeedback unit (PBU)
Number of subjects: 40
Study 33577235 — intervention group
Group type: COMPARATOR
Intervention: Control group (none)
Number of subjects: 40
Study 32370731 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 600mg ALA twice daily for 6 months
Number of subjects: 200
Study 32370731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 36890541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) administration (1000 mg before skin incision and 6 hours after)
Number of subjects: 59
Study 36890541 — intervention group
Group type: COMPARATOR
Intervention: Control group (without TXA administration)
Number of subjects: 59
Study 36890541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) administration
Number of subjects: 59
Study 34936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg
Number of subjects: 0
Study 34936382 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole (TMP/SMX)
Number of subjects: 0
Study 34936382 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 20 mg
Number of subjects: 0
Study 34936382 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin
Number of subjects: 0
Study 34936382 — intervention group
Group type: COMPARATOR
Intervention: Untreated controls
Number of subjects: 0
Study 34936382 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects receiving antibiotics
Number of subjects: 0
Study 32217888 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (electro or sham)
Number of subjects: 108
Study 32217888 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological hot flash treatment (gabapentin or placebo)
Number of subjects: 108
Study 33997903 — intervention group
Group type: EXPERIMENTAL
Intervention: Health information exchange (HIE) event notification intervention
Number of subjects: 23
Study 34432899 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (2.2 mg on days 1 and 2; 13.2 mg on days 3 and 4)
Number of subjects: 26
Study 34432899 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (400 mg twice on day 1, then 3 doses of 200 mg every 12 hours)
Number of subjects: 26
Study 34432899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 33647066 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight NHBs at baseline
Number of subjects: 70750
Study 33647066 — intervention group
Group type: EXPERIMENTAL
Intervention: NHBs in general
Number of subjects: 70750
Study 33647066 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-stratified results for NHBs
Number of subjects: 70750